T
Tuba Bas
Researcher at Bristol-Myers Squibb
Publications - 14
Citations - 1457
Tuba Bas is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Pembrolizumab & Transmembrane protein. The author has an hindex of 9, co-authored 13 publications receiving 476 citations. Previous affiliations of Tuba Bas include Worcester Polytechnic Institute & Merck & Co..
Papers
More filters
Journal ArticleDOI
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish M. Gadgeel,Delvys Rodriguez-Abreu,Giovanna Speranza,Emilio Esteban,Enriqueta Felip,Manuel Domine,Rina Hui,Maximilian Hochmair,Philip Clingan,Steven Francis Powell,Susanna Yee Shan Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Edward B. Garon,Silvia Novello,Belén Rubio-Viqueira,Michael Boyer,Takayasu Kurata,Jhanelle E. Gray,J. Yang,Tuba Bas,M. Catherine Pietanza,Marina Chiara Garassino +25 more
TL;DR: First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares,David Vicente,Ali Tafreshi,Andrew G. Robinson,Hector Soto Parra,Julien Mazieres,Barbara Hermes,Irfan Cicin,Balazs Medgyasszay,Jerónimo Rodríguez-Cid,Isamu Okamoto,Sung Sook Lee,Rodryg Ramlau,Vladimir Vladimirov,Ying Cheng,Xuan Deng,Ying Zhang,Tuba Bas,Bilal Piperdi,Balazs Halmos +19 more
TL;DR: The PFS-2 outcomes support pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous NSCLC.
Journal ArticleDOI
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Marcus O. Butler,Andrew F. Hill,Ivan Marquez-Rodas,John B. A. G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,Matteo S. Carlino,Céleste Lebbé,Grant A. McArthur,Paolo A. Ascierto,Gregory A. Daniels,Georgina V. Long,Tuba Bas,Corey Ritchings,James Larkin,F. Stephen Hodi +28 more
TL;DR: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolaumab alone versus IPILimumab as discussed by the authors.
Journal ArticleDOI
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,Charles Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Marcus O. Butler,Andrew G. Hill,Ivan Marquez-Rodas,John B. A. G. Haanen,Tuba Bas,Wim van Dijck,James Larkin,F. Stephen Hodi +19 more
TL;DR: This 6.5-y analysis represents the longest follow-up from a phase 3 melanoma trial in the modern checkpoint inhibitor combination therapy and targeted therapy era and shows durable improved outcomes with NIVO + IPI and NivO vs IPI in pts with advanced melanoma.
Journal ArticleDOI
KCNE1 subunits require co-assembly with K+ channels for efficient trafficking and cell surface expression
TL;DR: The data suggest that the errant KCNE1 trafficking observed in human embryonic kidney cells may be due, in part, to the presence of endogenous voltage-gated K+ channels in these cells.